Pulse Biosciences (NASDAQ:PLSE) Stock Rating Upgraded by StockNews.com

StockNews.com upgraded shares of Pulse Biosciences (NASDAQ:PLSE) to a sell rating in a report released on Monday morning.

Pulse Biosciences Price Performance

Shares of NASDAQ:PLSE opened at $16.09 on Monday. The firm has a 50 day moving average of $18.78 and a 200 day moving average of $18.15. Pulse Biosciences has a 52 week low of $6.60 and a 52 week high of $25.00.

Institutional Investors Weigh In On Pulse Biosciences

Institutional investors have recently added to or reduced their stakes in the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Pulse Biosciences by 14.2% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 38,308 shares of the company’s stock valued at $667,000 after buying an additional 4,773 shares during the last quarter. Panoramic Capital LLC bought a new position in shares of Pulse Biosciences during the 4th quarter worth approximately $846,000. Deutsche Bank AG lifted its position in Pulse Biosciences by 65.1% during the fourth quarter. Deutsche Bank AG now owns 16,795 shares of the company’s stock valued at $292,000 after acquiring an additional 6,625 shares during the last quarter. Bank of America Corp DE boosted its stake in Pulse Biosciences by 0.4% in the fourth quarter. Bank of America Corp DE now owns 788,454 shares of the company’s stock valued at $13,727,000 after acquiring an additional 2,884 shares in the last quarter. Finally, Tower Research Capital LLC TRC grew its holdings in Pulse Biosciences by 98.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,692 shares of the company’s stock worth $29,000 after purchasing an additional 838 shares during the last quarter. Institutional investors own 76.95% of the company’s stock.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.